Papaverine Revisited as a Hepatotoxin

Publisher Website
Google Scholar
Abstract
The proliferation of therapeutic agents during the past quarter-century has been accompanied by an increased frequency of drug-induced hepatic disease.1 , 2 Usually, the ability of an agent to produce hepatic injury is recognized within a few years of its introduction into clinical use. Accordingly, the convincing report of hepatic disease induced by papaverine in this issue of the Journal comes as a surprise after more than a half-century of its uneventful clinical use. Reasons for the long oversight are suggested by the authors.The authors' deduction that hypersensitivity to the drug was responsible is consistent with the period of three to . . .

This publication has 4 references indexed in Scilit: